Cancer Family
Squamous Cell Neoplasm
CI-CAN-00000359Explore in graph →
Non-malignant1,025 active trials9 approved drugs78 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000359Explore in graph →
Clinical trials
3,210 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07705412 | Postoperative Radiotherapy and Lymph Node Dissection After Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma | completed | — | 465 | Tongji HospitalOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT03712566 | Multi-Omic Assessment of Squamous Cell Cancers Receiving Systemic Therapy(MASST) | active not recruiting | — | 39 | University Health Network, TorontoOTHER | 1 | Jul 14, 2026 |
| clinicaltrials |
| NCT07214987 | PDT For Induction Therapy For Head And Neck Cancer | recruiting | Phase 2 | 26 | Massachusetts General HospitalOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07435324 | A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma | completed | Phase 3 | 161 | R-PharmINDUSTRY | 2 | Jul 14, 2026 | clinicaltrials |
| NCT07701681 | Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma | not yet recruiting | Phase 2 | 75 | Sun Yat-sen UniversityOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07702253 | O-GlcNAcylation Induced HMGB1 Signalling | active not recruiting | — | 120 | Chinese University of Hong KongOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT02186847 | Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer | completed | Phase 2 | 170 | NRG OncologyOTHER | 3 | Jul 13, 2026 | clinicaltrials |
| NCT04858269 | First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients | active not recruiting | Phase 2 | 31 | Wake Forest University Health SciencesOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06490003 | Predicting Postoperative Chemotherapy Efficacy in Patients With Esophageal Squamous Cell Carcinoma | recruiting | — | 150 | City of Hope Medical CenterOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07697287 | Oral Mucositis Management in Patients Receiving Radiation for Head and Neck Cancer: An Evaluation of a Barrier Based Treatment(TOPHAT) | active not recruiting | Phase 4 | 29 | McMaster UniversityOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07697859 | PD-1 Inhibitors Combined With Local Therapy at Different Timings in Oligometastatic ESCC(ESO-shanghai31) | recruiting | — | 354 | Fudan UniversityOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07697898 | TDLN-Guided Lymphadenectomy After Neoadjuvant Immunochemotherapy for ESCC | not yet recruiting | — | 400 | Tongji HospitalOTHER | 0 | Jul 13, 2026 | clinicaltrials |
| NCT07699185 | Neoadjuvant Cardonilizumab Combined With Neoadjuvant Chemoradiotherapy Can Resect Locally Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 336 | Tongji HospitalOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07697040 | Becotatug Vedotin Plus Cisplatin and Radiotherapy in LA-ESCC | not yet recruiting | Phase 1 | 12 | Hebei Medical University Fourth HospitalOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT03114319 | Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 | 227 | Novartis PharmaceuticalsINDUSTRY | 9 | Jul 9, 2026 | clinicaltrials |
| NCT07586124 | Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma | recruiting | Phase 2 | 80 | Lepu Biopharma Co., Ltd.INDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07601737 | Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma | recruiting | Phase 2 | 182 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07692152 | Sintilimab Versus Mitomycin in Combination With Capecitabine and IMRT for Limited-stage Anal Squamous Cell Carcinoma | recruiting | Phase 3 | 350 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07692360 | Salivary IL-6 and Interleukin Gene Polymorphisms in Oral Squamous Cell Carcinoma(IL6-OSCC) | not yet recruiting | — | 38 | University of PaviaOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT03603808 | VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions | completed | Phase 2 | 44 | AIDS Malignancy ConsortiumNETWORK | 2 | Jul 8, 2026 | clinicaltrials |
| NCT04291105 | Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients | active not recruiting | Phase 2 | 87 | Vyriad, Inc.INDUSTRY | 2 | Jul 8, 2026 | clinicaltrials |
| NCT06288191 | Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma | recruiting | Phase 2 | 20 | Melanoma Institute AustraliaOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06797986 | A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects With HPV Positive HNSCC. | recruiting | Phase 1 / Phase 2 | 37 | Cellid Co., Ltd.INDUSTRY | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06979180 | A Clinical Trial to Investigate the Safety and Efficacy of Papillex® on Abnormal Cervical Cells Caused by HPV. | recruiting | N/A | 60 | Papillex Inc.INDUSTRY | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07567235 | Clinical Study of CFH Protein Via Ice Microneedles for Radiation-Induced Skin Fibrosis | recruiting | Phase 1 | 9 | West China HospitalOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07578467 | Combining Neo-adjuvant ATR-inhibition With Nodal SBRT for Early-stage Resectable HPV+ OPSCCs | not yet recruiting | Phase 1 / Phase 2 | 35 | Abramson Cancer Center at Penn MedicineOTHER | 0 | Jul 8, 2026 | clinicaltrials |
| NCT06165380 | Cardenilimab Combined With Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma | active not recruiting | Phase 2 | 43 | Li ZhangOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06403436 | A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors(TT-CSP-001) | completed | Phase 1 | 45 | TOLREMO therapeutics AGINDUSTRY | 3 | Jul 7, 2026 | clinicaltrials |
| NCT06996249 | Prospective Data Collection Initiative on Thoracic Malignancies(DuTOC) | recruiting | — | 12,000 | Dutch Society of Physicians for Pulmonology and TuberculosisOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07149207 | Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors | recruiting | Phase 2 | 30 | Medical University of South CarolinaOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07224750 | A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer(MiGIC) | recruiting | — | 1,000 | City of Hope Medical CenterOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07403136 | Becotatug Vedotin ± Anti-PD-1 in Pretreated Advanced ESCC | recruiting | Phase 2 | 104 | Fudan UniversityOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07460765 | Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) | recruiting | Phase 1 | 40 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07686575 | Objective Response Rate of Ivonescimab With Chemotherapy in Locally Advanced Resectable Oral and Oropharyngeal Squamous Cell Carcinoma | recruiting | — | 20 | Zhujiang HospitalOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07688291 | A Phase II Study of PD-1/IL-2α-bias Bispecific Antibody Fusion Protein Monotherapy in Advanced Esophageal Squamous Cell Carcinoma After Failure of Prior ICI Plus Platinum-Based Chemotherapy | not yet recruiting | Phase 2 | 40 | Beijing GoBroad HospitalOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT04389632 | A Study of Sigvotatug Vedotin in Advanced Solid Tumors | recruiting | Phase 1 | 1,006 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 7 | Jul 6, 2026 | clinicaltrials |
| NCT04609566 | Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors | completed | Phase 2 | 161 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT04831320 | Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor | active not recruiting | Phase 2 | 46 | Washington University School of MedicineOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07136545 | A Phase I/II Trial of HCB101 in Combination With Pembrolizumab for Patients With Platinum-Refractory, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SirH&N Trial) | recruiting | Phase 1 / Phase 2 | 50 | Taipei Veterans General Hospital, TaiwanOTHER_GOV | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07683507 | Becotatug Vedotin Plus PD-1 Inhibitor for Head and Neck Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 60 | Feng LiuOTHER | 0 | Jul 6, 2026 | clinicaltrials |
| NCT03952585 | De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer | active not recruiting | Phase 2 / Phase 3 | 384 | National Cancer Institute (NCI)NIH | 2 | Jul 2, 2026 | clinicaltrials |
| NCT05070403 | Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma | active not recruiting | Phase 2 | 35 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT05522881 | The Registry Study of Genetic Alterations of Oropharyngeal Cancer in Taiwan | recruiting | — | 410 | National Health Research Institutes, TaiwanOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT06919666 | NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | active not recruiting | Phase 1 / Phase 2 | 29 | University of Colorado, DenverOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07169734 | A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors | recruiting | Phase 1 / Phase 2 | 180 | Alentis Therapeutics AGINDUSTRY | 8 | Jul 2, 2026 | clinicaltrials |
| NCT07680088 | Phase 2 Study of Pembrolizumab and Lenvatinib in Anal Squamous Cell Cancer | not yet recruiting | Phase 2 | 17 | University of Texas Southwestern Medical CenterOTHER | 0 | Jul 2, 2026 | clinicaltrials |
| NCT07682285 | Taiwanese Green Propolis for Lipid Profiles, Fatigue, and Quality of Life in Oral Cavity Cancer Survivors(TGP-OCS) | completed | N/A | 25 | Taipei Medical UniversityOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07682376 | Low-Dose Radiotherapy With Retlirafusp Alfa and Chemotherapy as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma | active not recruiting | Phase 2 | 96 | Harbin Medical UniversityOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT01772706 | Laser Mucite ORL : Effectiveness of Laser Therapy for Mucositis Induced by a Radio-chemotherapy in Head and Neck Cancer(LaserMucite) | completed | N/A | 97 | Institut Cancerologie de l'OuestOTHER | 1 | Jul 1, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 15, 2026source: clinicaltrials